Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00950,Fexofenadine
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00950,Fexofenadine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],53.9,5277,DB00950,Fexofenadine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],90.7,5278,DB00950,Fexofenadine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],16.5,5279,DB00950,Fexofenadine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],20.0,5280,DB00950,Fexofenadine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[pg] / [ml],80.8,5281,DB00950,Fexofenadine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[pg] / [ml],101,5282,DB00950,Fexofenadine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],263,5283,DB00950,Fexofenadine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],435,5284,DB00950,Fexofenadine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],54.5,5285,DB00950,Fexofenadine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],75.7,5286,DB00950,Fexofenadine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·pg] / [ml],467,5287,DB00950,Fexofenadine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·pg] / [ml],556,5288,DB00950,Fexofenadine
,32557079,AUC0-∞R,The maternal pharmacokinetics of fexofenadine was enantioselective (AUC0-∞R-(+)/S-(-) ~ 1.5) in both control and interaction groups.,Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),,1.5,7873,DB00950,Fexofenadine
,32557079,AUC0-∞,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[h·ng] / [ml],267.7,7874,DB00950,Fexofenadine
,32557079,AUC0-∞,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[h·ng] / [ml],376.1,7875,DB00950,Fexofenadine
,32557079,oral total clearance,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[l] / [h],105.1,7876,DB00950,Fexofenadine
,32557079,oral total clearance,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[l] / [h],74.4,7877,DB00950,Fexofenadine
,18294330,"AUC(0,24 h)","After placebo administration, mean AUC(0,24 h) of S- and R-fexofenadine was 474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101), respectively.",The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294330/),[h·ng] / [ml],474,11102,DB00950,Fexofenadine
,18294330,"AUC(0,24 h)","After placebo administration, mean AUC(0,24 h) of S- and R-fexofenadine was 474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101), respectively.",The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294330/),[h·ng] / [ml],798,11103,DB00950,Fexofenadine
,28301431,hepatic,"The hepatic and intestinal extraction ratios for midazolam were 0.11 ± 0.06 and 0.64 ± 0.25, respectively; however, CYP3A4 activity was nearly 5-fold lower in our CD cohort compared with published data among healthy subjects.",CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301431/),,0.11,12020,DB00950,Fexofenadine
,28301431,in,"The hepatic and intestinal extraction ratios for midazolam were 0.11 ± 0.06 and 0.64 ± 0.25, respectively; however, CYP3A4 activity was nearly 5-fold lower in our CD cohort compared with published data among healthy subjects.",CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301431/),,0.11,12021,DB00950,Fexofenadine
,9871426,steady-state maximum plasma concentration,"Single-dose mean concentration ranged from 46 to 6383 ng/mL, and steady-state maximum plasma concentration ranged from 58 to 4677 ng/mL.","Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871426/),[ng] / [ml],58 to 4677,12518,DB00950,Fexofenadine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],1701,13330,DB00950,Fexofenadine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],3554,13331,DB00950,Fexofenadine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],4308,13332,DB00950,Fexofenadine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],4107,13333,DB00950,Fexofenadine
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],214,13334,DB00950,Fexofenadine
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],77,13335,DB00950,Fexofenadine
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],2,13336,DB00950,Fexofenadine
,18585287,flow rate,"The chromatographic separation was achieved using a Supelco C(18)-DB (250 mm x 4.6mm I.D./5 microm particle size) column with mobile phase comprising of ammonium acetate buffer and acetonitrile (63:37, v/v), delivered isocratically at a flow rate of 1.0 mL min(-1).",A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma--application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585287/),[ml] / [min],1.0,16964,DB00950,Fexofenadine
,18585287,time of analysis,"The advantages of our method are small sample volume (100 microL), short time of analysis (13 min) and a simple sample extraction and clean-up as compared to the previously published methods.",A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma--application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585287/),min,13,16965,DB00950,Fexofenadine
,11824810,limit of quantification,The limit of quantification achieved with this method was 0.5 ng/ml in plasma and 1.0 ng in 50 microl of urine.,Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824810/),[ng] / [ml],0.5,18736,DB00950,Fexofenadine
,11824810,limit of quantification,The limit of quantification achieved with this method was 0.5 ng/ml in plasma and 1.0 ng in 50 microl of urine.,Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824810/),ng,1.0,18737,DB00950,Fexofenadine
,17221908,linear dynamic,The method exhibited a linear dynamic range of 1-500 ng/mL for fexofenadine in human plasma.,Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221908/),[ng] / [ml],1-500,19833,DB00950,Fexofenadine
,17221908,total chromatographic run time,The total chromatographic run time of 2 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221908/),min,2,19834,DB00950,Fexofenadine
,32365695,zeta potential,The optimized formulation containing Capryol 90 as absorption enhancer has a mean particle size 202.6 ± 3.9 nm and zeta potential -31.6 ± 0.9 mV.,Quality by Design for the Development and Analysis of Enhanced In-Situ Forming Vesicles for the Improvement of the Bioavailability of Fexofenadine HCl in Vitro and in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32365695/),mv,31.6,30136,DB00950,Fexofenadine
,32365695,entrapment efficiency,It achieved high entrapment efficiency of the drug 73.7 ± 1.7% and rapid Q3h release reaches 71.5 ± 2.7%.,Quality by Design for the Development and Analysis of Enhanced In-Situ Forming Vesicles for the Improvement of the Bioavailability of Fexofenadine HCl in Vitro and in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32365695/),%,73.7,30137,DB00950,Fexofenadine
,32365695,Q3h release,It achieved high entrapment efficiency of the drug 73.7 ± 1.7% and rapid Q3h release reaches 71.5 ± 2.7%.,Quality by Design for the Development and Analysis of Enhanced In-Situ Forming Vesicles for the Improvement of the Bioavailability of Fexofenadine HCl in Vitro and in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32365695/),%,71.5,30138,DB00950,Fexofenadine
,21593283,AUC(0-24),"The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD.","Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593283/),[h·ng] / [ml],775,35046,DB00950,Fexofenadine
,21593283,AUC(0-24),"The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD.","Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593283/),[h·ng] / [ml],1097,35047,DB00950,Fexofenadine
,21593283,AUC(0-24),"The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD.","Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593283/),[h·ng] / [ml],1547,35048,DB00950,Fexofenadine
,16515667,terminal half-life,"After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),h,2.4,40218,DB00950,Fexofenadine
,16515667,apparent volume of distribution,"After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),[l] / [kg],0.8,40219,DB00950,Fexofenadine
,16515667,total body clearance,"After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),[l] / [h·kg],0.8,40220,DB00950,Fexofenadine
,16515667,bioavailability,After oral administration of fexofenadine at 10 mg/kg bw bioavailability was 2.6% (1.9-2.9%).,"Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),%,2.6,40221,DB00950,Fexofenadine
,16515667,bioavailability,"Ivermectin pretreatment (0.2 mg/kg, p.o.) 12 h before oral fexofenadine decreased the bioavailability to 1.5% (1.4-2.1%).","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),%,1.5,40222,DB00950,Fexofenadine
,16515667,maximal duration,"Oral and i.v. fexofenadine significantly decreased histamine-induced wheal formation, with a maximal duration of 6 h.","Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),h,6,40223,DB00950,Fexofenadine
,16515667,EC50,A pharmacokinetic/pharmacodynamic link model indicated that fexofenadine in horse has antihistaminic effects at low plasma concentrations (EC50 = 16 ng/mL).,"Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515667/),[ng] / [ml],16,40224,DB00950,Fexofenadine
,19655405,area under the curve between 0-12 hours (AUC(0-12)),"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[min·ng] / [ml],102490.7,47595,DB00950,Fexofenadine
,19655405,area under the curve between 0-12 hours (AUC(0-12)),"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[min·ng] / [ml],49933.3,47596,DB00950,Fexofenadine
,19655405,Cmax,"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[ng] / [ml],1102.0,47597,DB00950,Fexofenadine
,19655405,Cmax,"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[ng] / [ml],274.3,47598,DB00950,Fexofenadine
,24424850,flow rate,"The chromatographic resolution was achieved on a Chromolith RP18e column using an isocratic mobile phase consisting of 20 mm ammonium formate-acetonitrile (20:80, v/v) at flow rate of 1.2 mL/min.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),[ml] / [min],1.2,55640,DB00950,Fexofenadine
,24424850,total run time of analysis,"The total run time of analysis was 4 min and elution of MT, FF, MT-d6 and FF-d10 occurred at 2.5, 1.2, 2.4 and 1.2 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),min,4,55641,DB00950,Fexofenadine
,24424850,total run time of analysis,"The total run time of analysis was 4 min and elution of MT, FF, MT-d6 and FF-d10 occurred at 2.5, 1.2, 2.4 and 1.2 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),min,2.5,55642,DB00950,Fexofenadine
,24424850,total run time of analysis,"The total run time of analysis was 4 min and elution of MT, FF, MT-d6 and FF-d10 occurred at 2.5, 1.2, 2.4 and 1.2 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424850/),min,1.2,55643,DB00950,Fexofenadine
,24075962,terminal half-life,FEX had a terminal half-life of 1.7h and a liver extraction of 3%.,Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24075962/),h,1.7,58641,DB00950,Fexofenadine
,24075962,liver extraction,FEX had a terminal half-life of 1.7h and a liver extraction of 3%.,Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24075962/),%,3,58642,DB00950,Fexofenadine
,27981349,maximum plasma concentration,Treatment with PIP significantly increased maximum plasma concentration of FEX [406.9 (control) vs. 767 ng/mL (treatment)] and area under the plasma concentration-time curve [3403.7 (control) vs. 5724.7 ng.h/mL (treatment)] when compared to the control phase.,"The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27981349/),[ng] / [ml],406.9,58987,DB00950,Fexofenadine
,27981349,maximum plasma concentration,Treatment with PIP significantly increased maximum plasma concentration of FEX [406.9 (control) vs. 767 ng/mL (treatment)] and area under the plasma concentration-time curve [3403.7 (control) vs. 5724.7 ng.h/mL (treatment)] when compared to the control phase.,"The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27981349/),[ng] / [ml],767,58988,DB00950,Fexofenadine
,27981349,area under the plasma concentration-time curve,Treatment with PIP significantly increased maximum plasma concentration of FEX [406.9 (control) vs. 767 ng/mL (treatment)] and area under the plasma concentration-time curve [3403.7 (control) vs. 5724.7 ng.h/mL (treatment)] when compared to the control phase.,"The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27981349/),[h·ng] / [ml],3403.7,58989,DB00950,Fexofenadine
,27981349,area under the plasma concentration-time curve,Treatment with PIP significantly increased maximum plasma concentration of FEX [406.9 (control) vs. 767 ng/mL (treatment)] and area under the plasma concentration-time curve [3403.7 (control) vs. 5724.7 ng.h/mL (treatment)] when compared to the control phase.,"The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27981349/),[h·ng] / [ml],5724.7,58990,DB00950,Fexofenadine
,27981349,apparent oral clearance,"In contrast, PIP treatment significantly decreased apparent oral clearance of FEX [35.4 (control) vs. 20.7 L/h (treatment)] as compared to the control.","The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27981349/),[l] / [h],35.4,58991,DB00950,Fexofenadine
,27981349,apparent oral clearance,"In contrast, PIP treatment significantly decreased apparent oral clearance of FEX [35.4 (control) vs. 20.7 L/h (treatment)] as compared to the control.","The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27981349/),[l] / [h],20.7,58992,DB00950,Fexofenadine
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],101,61552,DB00950,Fexofenadine
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],2 540,61553,DB00950,Fexofenadine
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],23 900,61554,DB00950,Fexofenadine
,25176380,Tmax,"After oral administration of fexofenadine, the Tmax was 1.90 ± 0.81h.",Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176380/),h,1.90,61935,DB00950,Fexofenadine
,25176380,Cmax,The Cmax was 703.76 ± 298.94ng/mL and AUC0-oo was 4582.52 ± 1812.59h´ng/mL.,Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176380/),[ng] / [ml],703.76,61936,DB00950,Fexofenadine
,25176380,AUC0-oo,The Cmax was 703.76 ± 298.94ng/mL and AUC0-oo was 4582.52 ± 1812.59h´ng/mL.,Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176380/),[h´ng] / [ml],4582.52,61937,DB00950,Fexofenadine
,25176380,elimination half-life,The elimination half-life of fexofenadine was 12.18 ± 3.61h.,Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176380/),h,12.18,61938,DB00950,Fexofenadine
,33825113,placental transfer rates,The placental transfer rates were similar between (S)-(-)- and (R)-(+)-fexofenadine in both Control (0.0024 vs 0.0019 min-1) and Interaction (0.0019 vs 0.0021 min-1) periods.,Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825113/),1/[min],0.0024,63727,DB00950,Fexofenadine
,33825113,placental transfer rates,The placental transfer rates were similar between (S)-(-)- and (R)-(+)-fexofenadine in both Control (0.0024 vs 0.0019 min-1) and Interaction (0.0019 vs 0.0021 min-1) periods.,Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825113/),1/[min],0.0019,63728,DB00950,Fexofenadine
,33825113,placental transfer rates,The placental transfer rates were similar between (S)-(-)- and (R)-(+)-fexofenadine in both Control (0.0024 vs 0.0019 min-1) and Interaction (0.0019 vs 0.0021 min-1) periods.,Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825113/),1/[min],0.0021,63729,DB00950,Fexofenadine
,24490806,oral bioavailability,"Fexofenadine hydrochloride (FXD) is a slightly soluble, bitter-tasting, drug having an oral bioavailability of 35%.","Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),%,35,70023,DB00950,Fexofenadine
,24490806,T(max),The maximum plasma concentration is reached 2.6 h (T(max)) post-dose.,"Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),h,2.6,70024,DB00950,Fexofenadine
,24490806,f(2),Drug release profiles of F23 and the phenylalanine-containing Allegra(®) ODT were similar (f(2) = 96).,"Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),,96,70025,DB00950,Fexofenadine
,21904453,relative bioavailability,The relative bioavailability of FEX microemulsion was about 376.76% compared with commercial syrup in rabbits.,Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904453/),%,376.76,74417,DB00950,Fexofenadine
,15536457,AUC(0-24),"As compared with the 2677GG/3435CC subjects, the AUC(0-24) values were 17% lower in the 2677AA/3435CC subjects and 47% higher in the 2677TT/3435TT subjects (GG/CC versus AA/CC versus TT/TT, 4017 +/- 1137 ng . h/mL versus 3315 +/- 958 ng . h/mL versus 5934 +/- 2,064 ng . h/mL; P=.018).",A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536457/),[h·ng] / [ml],4017,82849,DB00950,Fexofenadine
,15536457,AUC(0-24),"As compared with the 2677GG/3435CC subjects, the AUC(0-24) values were 17% lower in the 2677AA/3435CC subjects and 47% higher in the 2677TT/3435TT subjects (GG/CC versus AA/CC versus TT/TT, 4017 +/- 1137 ng . h/mL versus 3315 +/- 958 ng . h/mL versus 5934 +/- 2,064 ng . h/mL; P=.018).",A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536457/),[h·ng] / [ml],3315,82850,DB00950,Fexofenadine
,15536457,AUC(0-24),"As compared with the 2677GG/3435CC subjects, the AUC(0-24) values were 17% lower in the 2677AA/3435CC subjects and 47% higher in the 2677TT/3435TT subjects (GG/CC versus AA/CC versus TT/TT, 4017 +/- 1137 ng . h/mL versus 3315 +/- 958 ng . h/mL versus 5934 +/- 2,064 ng . h/mL; P=.018).",A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536457/),[h·ng] / [ml],5934,82851,DB00950,Fexofenadine
,15536457,AUC(0-24),"By stratification for genotypes at position 3435, homozygous 3435TT subjects were found to have significantly higher AUC(0-24) (P=.024) and maximum plasma concentration (P=.040) values than CC subjects [AUC(0-24), 5934 +/- 2064 ng .",A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536457/),ng,5934,82852,DB00950,Fexofenadine
,15536457,maximum plasma concentration,"h/mL versus 3998 +/- 1241 ng . h/mL; maximum plasma concentration, 958 +/- 408 ng/mL versus 673 +/- 242 ng/mL].",A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536457/),[ng] / [ml],958,82853,DB00950,Fexofenadine
,15536457,maximum plasma concentration,"h/mL versus 3998 +/- 1241 ng . h/mL; maximum plasma concentration, 958 +/- 408 ng/mL versus 673 +/- 242 ng/mL].",A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536457/),[ng] / [ml],673,82854,DB00950,Fexofenadine
,23422332,T1/2,"Pharamcokinetic parameters in the placebo phase were as follows: T1/2 (3.75±1.47h), Cmax (745.11±137.41μg/L), Tmax (2.25±0.47h), AUC(0-t) (3894.27±923.45μgh/L), AUC(0-∞) (3993.84±912.97μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),h,3.75,83075,DB00950,Fexofenadine
,23422332,Cmax,"Pharamcokinetic parameters in the placebo phase were as follows: T1/2 (3.75±1.47h), Cmax (745.11±137.41μg/L), Tmax (2.25±0.47h), AUC(0-t) (3894.27±923.45μgh/L), AUC(0-∞) (3993.84±912.97μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),[μg] / [l],745.11,83076,DB00950,Fexofenadine
,23422332,Tmax,"Pharamcokinetic parameters in the placebo phase were as follows: T1/2 (3.75±1.47h), Cmax (745.11±137.41μg/L), Tmax (2.25±0.47h), AUC(0-t) (3894.27±923.45μgh/L), AUC(0-∞) (3993.84±912.97μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),h,2.25,83077,DB00950,Fexofenadine
,23422332,AUC(0-t),"Pharamcokinetic parameters in the placebo phase were as follows: T1/2 (3.75±1.47h), Cmax (745.11±137.41μg/L), Tmax (2.25±0.47h), AUC(0-t) (3894.27±923.45μgh/L), AUC(0-∞) (3993.84±912.97μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),[μgh] / [l],3894.27,83078,DB00950,Fexofenadine
,23422332,AUC(0-∞),"Pharamcokinetic parameters in the placebo phase were as follows: T1/2 (3.75±1.47h), Cmax (745.11±137.41μg/L), Tmax (2.25±0.47h), AUC(0-t) (3894.27±923.45μgh/L), AUC(0-∞) (3993.84±912.97μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),[μgh] / [l],3993.84,83079,DB00950,Fexofenadine
,23422332,T1/2,"Pharamcokinetic parameters in the RA extract phase were as follows: T1/2 (4.00±1.24h), Cmax (709.44±170.03μg/L), Tmax (2.21±0.51h), AUC(0-t) (3832.72±1077.60μgh/L), AUC(0-∞) (3983.53±1019.83μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),h,4.00,83080,DB00950,Fexofenadine
,23422332,Cmax,"Pharamcokinetic parameters in the RA extract phase were as follows: T1/2 (4.00±1.24h), Cmax (709.44±170.03μg/L), Tmax (2.21±0.51h), AUC(0-t) (3832.72±1077.60μgh/L), AUC(0-∞) (3983.53±1019.83μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),[μg] / [l],709.44,83081,DB00950,Fexofenadine
,23422332,Tmax,"Pharamcokinetic parameters in the RA extract phase were as follows: T1/2 (4.00±1.24h), Cmax (709.44±170.03μg/L), Tmax (2.21±0.51h), AUC(0-t) (3832.72±1077.60μgh/L), AUC(0-∞) (3983.53±1019.83μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),h,2.21,83082,DB00950,Fexofenadine
,23422332,AUC(0-t),"Pharamcokinetic parameters in the RA extract phase were as follows: T1/2 (4.00±1.24h), Cmax (709.44±170.03μg/L), Tmax (2.21±0.51h), AUC(0-t) (3832.72±1077.60μgh/L), AUC(0-∞) (3983.53±1019.83μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),[μgh] / [l],3832.72,83083,DB00950,Fexofenadine
,23422332,AUC(0-∞),"Pharamcokinetic parameters in the RA extract phase were as follows: T1/2 (4.00±1.24h), Cmax (709.44±170.03μg/L), Tmax (2.21±0.51h), AUC(0-t) (3832.72±1077.60μgh/L), AUC(0-∞) (3983.53±1019.83μgh/L).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),[μgh] / [l],3983.53,83084,DB00950,Fexofenadine
,23422332,T1/2,"In the placebo phase, T1/2 of fexofenadine in ABCB1 3435T mutation allele carriers was longer compared to ABCB1 3435CC carriers (4.43±1.44h vs. 2.54±0.21h, p<0.05).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),h,4.43,83085,DB00950,Fexofenadine
,23422332,T1/2,"In the placebo phase, T1/2 of fexofenadine in ABCB1 3435T mutation allele carriers was longer compared to ABCB1 3435CC carriers (4.43±1.44h vs. 2.54±0.21h, p<0.05).",Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23422332/),h,2.54,83086,DB00950,Fexofenadine
,20307657,CL,"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),[l] / [h],13,85623,DB00950,Fexofenadine
,20307657,CL(R),"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),[l] / [h],4.1,85624,DB00950,Fexofenadine
,20307657,V(ss),"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),l,54,85625,DB00950,Fexofenadine
,20307657,t(1/2),"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),h,16,85626,DB00950,Fexofenadine
,20307657,CL,"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),[l] / [h],16,85627,DB00950,Fexofenadine
,20307657,CL(R),"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),[l] / [h],6.2,85628,DB00950,Fexofenadine
,20307657,V(ss),"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),l,64,85629,DB00950,Fexofenadine
,20307657,t(1/2),"Microdose: CL 13L/h, CL(R) 4.1L/h, V(ss) 54L, t(1/2) 16h; therapeutic dose: CL 16L/h, CL(R) 6.2L/h, V(ss) 64L, t(1/2) 12h.",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),h,12,85630,DB00950,Fexofenadine
,20307657,absolute oral bioavailability,"The absolute oral bioavailability of fexofenadine was 0.35 (microdose 0.41, therapeutic dose 0.30).",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),,0.35,85631,DB00950,Fexofenadine
,20307657,absolute oral bioavailability,"The absolute oral bioavailability of fexofenadine was 0.35 (microdose 0.41, therapeutic dose 0.30).",Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307657/),,0.41,85632,DB00950,Fexofenadine
,27151911,peak maximum plasma concentration (Cmax),"Treatment with DSN significantly increased the peak maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of FEX by 49.2% (523.28 versus 780.63 ng/mL) and 64.4% (3459.48 versus 5687.74 ng h/mL), respectively as compared to control phase.",The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27151911/),[ng] / [ml],523.28,88963,DB00950,Fexofenadine
,27151911,peak maximum plasma concentration (Cmax),"Treatment with DSN significantly increased the peak maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of FEX by 49.2% (523.28 versus 780.63 ng/mL) and 64.4% (3459.48 versus 5687.74 ng h/mL), respectively as compared to control phase.",The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27151911/),[ng] / [ml],780.63,88964,DB00950,Fexofenadine
,27151911,area under the plasma concentration-time curve (AUC),"Treatment with DSN significantly increased the peak maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of FEX by 49.2% (523.28 versus 780.63 ng/mL) and 64.4% (3459.48 versus 5687.74 ng h/mL), respectively as compared to control phase.",The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27151911/),[h·ng] / [ml],3459.48,88965,DB00950,Fexofenadine
,27151911,area under the plasma concentration-time curve (AUC),"Treatment with DSN significantly increased the peak maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of FEX by 49.2% (523.28 versus 780.63 ng/mL) and 64.4% (3459.48 versus 5687.74 ng h/mL), respectively as compared to control phase.",The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27151911/),[h·ng] / [ml],5687.74,88966,DB00950,Fexofenadine
,27151911,apparent oral clearance (CL/F),"On the other hand, apparent oral clearance (CL/F) of FEX was significantly decreased by 41.3% (37.03 versus 21.75 L/h) and there was no significant change was observed in Tmax, T1/2, and CLr (renal clearance) upon treatment with DSN when compared to control.",The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27151911/),[l] / [h],37.03,88967,DB00950,Fexofenadine
,27151911,apparent oral clearance (CL/F),"On the other hand, apparent oral clearance (CL/F) of FEX was significantly decreased by 41.3% (37.03 versus 21.75 L/h) and there was no significant change was observed in Tmax, T1/2, and CLr (renal clearance) upon treatment with DSN when compared to control.",The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27151911/),[l] / [h],21.75,88968,DB00950,Fexofenadine
,16895540,clearance from the perfusate (CL),"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),[ml] / [min],5.9,96761,DB00950,Fexofenadine
,16895540,clearance from the perfusate (CL),"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),[ml] / [min],1.24,96762,DB00950,Fexofenadine
,16895540,clearance from the perfusate (CL),"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),,44,96763,DB00950,Fexofenadine
,16895540,clearance from the perfusate (CL),"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),,17,96764,DB00950,Fexofenadine
,16895540,CL,"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),[ml] / [min],10.0,96765,DB00950,Fexofenadine
,16895540,CLB,"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),[ml] / [min],2.7,96766,DB00950,Fexofenadine
,16895540,CLB,"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),,87,96767,DB00950,Fexofenadine
,16895540,CLB,"Notably, clearance from the perfusate (CL) and into the bile (CLB; 5.9 +/- 0.6 and 1.24 +/- 0.20 mL/min, respectively), L : P (44 +/- 11) and B : L (17 +/- 2) were all reduced (P < 0.05) in this group compared with control (CL 10.0 +/- 1.1 mL/min; CLB 2.7 +/- 0.5 mL/min; L : P 87 +/- 14; and B : L 30 +/- 4).",Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895540/),,30,96768,DB00950,Fexofenadine
,15821041,biliary excretion clearance,"In mice, biliary excretion clearance (17 ml/min/kg) accounted for almost 60% of the total body clearance (30 ml/min/kg).","P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821041/),[ml] / [kg·min],17,99933,DB00950,Fexofenadine
,15821041,total body clearance,"In mice, biliary excretion clearance (17 ml/min/kg) accounted for almost 60% of the total body clearance (30 ml/min/kg).","P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821041/),[ml] / [kg·min],30,99934,DB00950,Fexofenadine
,15821041,bioavailability,Comparing the pharmacokinetics after intravenous and oral administration indicated that the bioavailability of fexofenadine was at most 2% in mice.,"P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821041/),%,2,99935,DB00950,Fexofenadine
,22628163,oral bioavailability,"The prodrug, ethyl-FXD, has high membrane permeability but the oral bioavailability of FXD derived from ethyl-FXD was only 6.2%.",Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628163/),%,6.2,107162,DB00950,Fexofenadine
,22628163,hepatic availability (F(h),"However, the high blood protein binding of ethyl-FXD resulted in a high hepatic availability (F(h) = 88%).",Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628163/),%,88,107163,DB00950,Fexofenadine
,19739673,"K(mI,u)","For napsagatran hepatic uptake, no passive diffusion and no binding were detected in vitro besides the active transport (K(mI,u) = 88.4 +/- 8.1 microM, V(maxI) = 384 +/- 19 pmol/mg/min).",Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19739673/),μM,88.4,109298,DB00950,Fexofenadine
,19739673,V(maxI),"For napsagatran hepatic uptake, no passive diffusion and no binding were detected in vitro besides the active transport (K(mI,u) = 88.4 +/- 8.1 microM, V(maxI) = 384 +/- 19 pmol/mg/min).",Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19739673/),[pM] / [mg·min],384,109299,DB00950,Fexofenadine
,19739673,"K(mI,u)","Fexofenadine was rapidly taken up into rat hepatocytes (K(mI,u) = 271 +/- 35 microM, V(maxI) = 3162 +/- 274 pmol/mg/min), and some contribution of passive diffusion to the uptake (P(dif) = 2.08 +/- 0.67 microL/mg/min) was observed.",Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19739673/),μM,271,109300,DB00950,Fexofenadine
,19739673,V(maxI),"Fexofenadine was rapidly taken up into rat hepatocytes (K(mI,u) = 271 +/- 35 microM, V(maxI) = 3162 +/- 274 pmol/mg/min), and some contribution of passive diffusion to the uptake (P(dif) = 2.08 +/- 0.67 microL/mg/min) was observed.",Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19739673/),[pM] / [mg·min],3162,109301,DB00950,Fexofenadine
,19739673,P(dif),"Fexofenadine was rapidly taken up into rat hepatocytes (K(mI,u) = 271 +/- 35 microM, V(maxI) = 3162 +/- 274 pmol/mg/min), and some contribution of passive diffusion to the uptake (P(dif) = 2.08 +/- 0.67 microL/mg/min) was observed.",Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19739673/),[μl] / [mg·min],2.08,109302,DB00950,Fexofenadine
,31442620,AUC,"After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),,62,116459,DB00950,Fexofenadine
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],18,116460,DB00950,Fexofenadine
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],1.,116461,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],2955,119005,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],5524,119006,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],2632,119007,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],7091,119008,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],1760,119009,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],4608,119010,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],2210,119011,DB00950,Fexofenadine
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],4845,119012,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],77,119013,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],52,119014,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],72,119015,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],36,119016,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],106,119017,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],52,119018,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],76,119019,DB00950,Fexofenadine
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],46,119020,DB00950,Fexofenadine
,11240975,Half-life,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),min,150 to 230,119021,DB00950,Fexofenadine
,11240975,time to maximum concentration,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),min,130 to 205,119022,DB00950,Fexofenadine
,11240975,renal clearance,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],95 to 153,119023,DB00950,Fexofenadine
,11240975,fraction unbound,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),%,2.9,119024,DB00950,Fexofenadine
,11240975,fraction unbound,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),%,3.7,119025,DB00950,Fexofenadine
,11240975,serum trough rifampin concentration,No effect of age or sex on fexofenadine disposition or serum trough rifampin concentration (0.2 microg/mL to 1.8 microg/mL) was observed before or after rifampin treatment.,The effect of rifampin administration on the disposition of fexofenadine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[μg] / [ml],0.2,119026,DB00950,Fexofenadine
,11240975,serum trough rifampin concentration,No effect of age or sex on fexofenadine disposition or serum trough rifampin concentration (0.2 microg/mL to 1.8 microg/mL) was observed before or after rifampin treatment.,The effect of rifampin administration on the disposition of fexofenadine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[μg] / [ml],1.8,119027,DB00950,Fexofenadine
,19855315,peak plasma concentration,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [ml],176.6,119423,DB00950,Fexofenadine
,19855315,peak plasma concentration,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [ml],103.2,119424,DB00950,Fexofenadine
,19855315,area under the plasma concentration-time curve,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [h·ml],1058.4,119425,DB00950,Fexofenadine
,19855315,area under the plasma concentration-time curve,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [h·ml],604.8,119426,DB00950,Fexofenadine
>,19373887,IC(50),"CP-100,356 was devoid of inhibition (IC(50) >50 microM) against major human P450 enzymes including P4503A4.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,50,121222,DB00950,Fexofenadine
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,0.5,121223,DB00950,Fexofenadine
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.2,121224,DB00950,Fexofenadine
,19373887,IC(50),"Inhibition of prazosin transport (IC(50) approximately 1.5 +/- 0.3 microM) in human BCRP-transfected MDCKII cells by CP-100,356 confirmed the dual MDR1/BCRP inhibitory properties.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.5,121225,DB00950,Fexofenadine
,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,66,121226,DB00950,Fexofenadine
>,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,15,121227,DB00950,Fexofenadine
,16969767,linear dynamic ranges,"The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma.","Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),[ng] / [ml],1-500,123213,DB00950,Fexofenadine
,16969767,linear dynamic ranges,"The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma.","Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),[ng] / [ml],2-1000,123214,DB00950,Fexofenadine
,16969767,total chromatographic run time,The total chromatographic run time was 2 min and more than 400 human plasma samples could be analyzed in one day by running the system overnight.,"Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),min,2,123215,DB00950,Fexofenadine
,19728561,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of fexofenadine was 1206.3 +/- 619.0 ng/ml for the test and 1172.6 +/- 493.7 ng/ml for the reference formulation.,Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728561/),[ng] / [ml],1206.3,123704,DB00950,Fexofenadine
,19728561,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of fexofenadine was 1206.3 +/- 619.0 ng/ml for the test and 1172.6 +/- 493.7 ng/ml for the reference formulation.,Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728561/),[ng] / [ml],1172.6,123705,DB00950,Fexofenadine
,19728561,AUC0-infinity,"The mean AUC0-infinity of fexofenadine was 8911.4 +/- 3870.0 and 9363.9 +/- 2668.0 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728561/),[h·ng] / [ml],8911.4,123706,DB00950,Fexofenadine
,19728561,AUC0-infinity,"The mean AUC0-infinity of fexofenadine was 8911.4 +/- 3870.0 and 9363.9 +/- 2668.0 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19728561/),[h·ng] / [ml],9363.9,123707,DB00950,Fexofenadine
,20456735,C(max),The mean +/- SD of C(max) normalized to 60 mg dose after microdose and therapeutic dose were 379 +/- 147 and 275 +/- 145 ng/mL respectively.,"Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456735/),[ng] / [ml],379,129549,DB00950,Fexofenadine
,20456735,C(max),The mean +/- SD of C(max) normalized to 60 mg dose after microdose and therapeutic dose were 379 +/- 147 and 275 +/- 145 ng/mL respectively.,"Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456735/),[ng] / [ml],275,129550,DB00950,Fexofenadine
,20456735,AUC(last),The mean AUC(last) normalized to 60 mg dose after microdose and therapeutic dose were 1914 +/- 738 and 1431 +/- 432 ng/h/mL respectively.,"Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456735/),[ng] / [h·ml],1914,129551,DB00950,Fexofenadine
,20456735,AUC(last),The mean AUC(last) normalized to 60 mg dose after microdose and therapeutic dose were 1914 +/- 738 and 1431 +/- 432 ng/h/mL respectively.,"Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456735/),[ng] / [h·ml],1431,129552,DB00950,Fexofenadine
,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,0.9,129595,DB00950,Fexofenadine
> or =,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,3,129596,DB00950,Fexofenadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],0.4,129597,DB00950,Fexofenadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],1-1.2,129598,DB00950,Fexofenadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],5.4-5.8,129599,DB00950,Fexofenadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],49,129600,DB00950,Fexofenadine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,50-65,129601,DB00950,Fexofenadine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,33,129602,DB00950,Fexofenadine
,16690724,biliary excretion index (BEI),"The biliary excretion index (BEI) of fexofenadine, when generated by terfenadine metabolism, was not significantly different from the BEI of preformed fexofenadine (15 +/- 2% versus 19 +/- 2%, respectively).",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),%,15,131192,DB00950,Fexofenadine
,16690724,biliary excretion index (BEI),"The biliary excretion index (BEI) of fexofenadine, when generated by terfenadine metabolism, was not significantly different from the BEI of preformed fexofenadine (15 +/- 2% versus 19 +/- 2%, respectively).",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),%,19,131193,DB00950,Fexofenadine
,16690724,rate,"Pharmacokinetic modeling revealed that the rate constant for hepatocyte uptake was faster for terfenadine compared with preformed fexofenadine (2.5 versus 0.08 h(-1), respectively), whereas the biliary excretion rate constant for preformed fexofenadine exceeded that of terfenadine (0.44 versus 0.039 h(-1), respectively).",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),1/[h],2.5,131194,DB00950,Fexofenadine
,16690724,rate,"Pharmacokinetic modeling revealed that the rate constant for hepatocyte uptake was faster for terfenadine compared with preformed fexofenadine (2.5 versus 0.08 h(-1), respectively), whereas the biliary excretion rate constant for preformed fexofenadine exceeded that of terfenadine (0.44 versus 0.039 h(-1), respectively).",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),1/[h],0.08,131195,DB00950,Fexofenadine
,16690724,biliary excretion rate constant,"Pharmacokinetic modeling revealed that the rate constant for hepatocyte uptake was faster for terfenadine compared with preformed fexofenadine (2.5 versus 0.08 h(-1), respectively), whereas the biliary excretion rate constant for preformed fexofenadine exceeded that of terfenadine (0.44 versus 0.039 h(-1), respectively).",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),1/[h],0.44,131196,DB00950,Fexofenadine
,16690724,biliary excretion rate constant,"Pharmacokinetic modeling revealed that the rate constant for hepatocyte uptake was faster for terfenadine compared with preformed fexofenadine (2.5 versus 0.08 h(-1), respectively), whereas the biliary excretion rate constant for preformed fexofenadine exceeded that of terfenadine (0.44 versus 0.039 h(-1), respectively).",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),1/[h],0.039,131197,DB00950,Fexofenadine
,16690724,rate,"Interestingly, the rate constants for basolateral excretion of terfenadine and fexofenadine were comparable (3.2 versus 1.9 h(-1), respectively) and increased only slightly with DEX treatment.",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),1/[h],3.2,131198,DB00950,Fexofenadine
,16690724,rate,"Interestingly, the rate constants for basolateral excretion of terfenadine and fexofenadine were comparable (3.2 versus 1.9 h(-1), respectively) and increased only slightly with DEX treatment.",Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690724/),1/[h],1.9,131199,DB00950,Fexofenadine
,19629959,total chroma,"The total chromatographic runtime was approximately 3.0 min with retention time for fexofenadine and IS at approximately 1.9 and 2.1 min, respectively.",Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19629959/),min,3.0,133935,DB00950,Fexofenadine
,19629959,retention time,"The total chromatographic runtime was approximately 3.0 min with retention time for fexofenadine and IS at approximately 1.9 and 2.1 min, respectively.",Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19629959/),min,1.9,133936,DB00950,Fexofenadine
,19629959,retention time,"The total chromatographic runtime was approximately 3.0 min with retention time for fexofenadine and IS at approximately 1.9 and 2.1 min, respectively.",Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19629959/),min,2.1,133937,DB00950,Fexofenadine
,12580990,Peff,"Peff of fexofenadine was low according to the BCS (0.11 +/- 0.11 and 0.04 +/- 0.13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0.37, 0.51).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.11,135222,DB00950,Fexofenadine
,12580990,Peff,"Peff of fexofenadine was low according to the BCS (0.11 +/- 0.11 and 0.04 +/- 0.13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0.37, 0.51).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.04,135223,DB00950,Fexofenadine
,12580990,Peff,"After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 +/- 0.47 and 0.22 +/- 0.31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0.62, 0.27 for T1 0-100 min vs T2 0-100 min; -0.54, 0.34 for T1 0-100 min vs T2 100-200 min).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.29,135224,DB00950,Fexofenadine
,12580990,Peff,"After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 +/- 0.47 and 0.22 +/- 0.31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0.62, 0.27 for T1 0-100 min vs T2 0-100 min; -0.54, 0.34 for T1 0-100 min vs T2 100-200 min).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.22,135225,DB00950,Fexofenadine
,12580990,plasma AUC,"Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[μg] / [min·ml],55,135226,DB00950,Fexofenadine
,12580990,plasma AUC,"Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[μg] / [min·ml],51,135227,DB00950,Fexofenadine
,12580990,Total plasma AUC (0-720 min),"Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[min·ng] / [ml],318,135228,DB00950,Fexofenadine
,12580990,Total plasma AUC (0-720 min),"Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[min·ng] / [ml],426,135229,DB00950,Fexofenadine
,15193739,total time,"The peak was detected using a fluorescence detector set at Ex 220 nm and Em 290 nm, and the total time for a chromatographic separation was approximately 17 min.",Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193739/),min,17,139170,DB00950,Fexofenadine
,15193739,recoveries,Mean recoveries were 72.8-76.7% with coefficients of variation of 2.7-5.8%.,Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193739/),%,72.8-76.7,139171,DB00950,Fexofenadine
,19221726,area under the time versus concentration curve (AUC),"The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/mL, P < 0.001) and similarly the maximum plasma concentration (C(max)) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006).","Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19221726/),[h·ng] / [ml],"2,005.3",140867,DB00950,Fexofenadine
,19221726,area under the time versus concentration curve (AUC),"The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/mL, P < 0.001) and similarly the maximum plasma concentration (C(max)) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006).","Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19221726/),[h·ng] / [ml],"3,098.6",140868,DB00950,Fexofenadine
,19221726,maximum plasma concentration (C(max)),"The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/mL, P < 0.001) and similarly the maximum plasma concentration (C(max)) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006).","Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19221726/),[ng] / [ml],295.3,140869,DB00950,Fexofenadine
,19221726,maximum plasma concentration (C(max)),"The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/mL, P < 0.001) and similarly the maximum plasma concentration (C(max)) during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/mL, P = 0.006).","Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19221726/),[ng] / [ml],480.3,140870,DB00950,Fexofenadine
,19221726,oral clearance,"Although the oral clearance of fexofenadine was decreased significantly by 37% after quercetin treatment (61.4 versus 38.7 L/h, P < 0.001), no differences in the renal clearance and half-life were observed between placebo and quercetin phases.","Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19221726/),[l] / [h],61.4,140871,DB00950,Fexofenadine
,19221726,oral clearance,"Although the oral clearance of fexofenadine was decreased significantly by 37% after quercetin treatment (61.4 versus 38.7 L/h, P < 0.001), no differences in the renal clearance and half-life were observed between placebo and quercetin phases.","Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19221726/),[l] / [h],38.7,140872,DB00950,Fexofenadine
,19238656,hepatic,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141867,DB00950,Fexofenadine
,19238656,intestinal extraction,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141868,DB00950,Fexofenadine
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,37,141869,DB00950,Fexofenadine
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,95,141870,DB00950,Fexofenadine
,33256506,peak maximum plasma concentration (C max),"The peak maximum plasma concentration (C max) and the area under the plasma concentration-time curve from zero to infinity (AUCinf) mean value of FEX with BRE and placebo-treated groups were 699 ng/mL vs. 710 ng/mL and 2972.5 ng⋅h/mL vs. 3460.5 ng⋅h/mL, respectively.","Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33256506/),[ng] / [ml],699,146635,DB00950,Fexofenadine
,33256506,peak maximum plasma concentration (C max),"The peak maximum plasma concentration (C max) and the area under the plasma concentration-time curve from zero to infinity (AUCinf) mean value of FEX with BRE and placebo-treated groups were 699 ng/mL vs. 710 ng/mL and 2972.5 ng⋅h/mL vs. 3460.5 ng⋅h/mL, respectively.","Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33256506/),[ng] / [ml],710,146636,DB00950,Fexofenadine
,33256506,area under the plasma concentration-time curve from zero to infinity (AUCinf),"The peak maximum plasma concentration (C max) and the area under the plasma concentration-time curve from zero to infinity (AUCinf) mean value of FEX with BRE and placebo-treated groups were 699 ng/mL vs. 710 ng/mL and 2972.5 ng⋅h/mL vs. 3460.5 ng⋅h/mL, respectively.","Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33256506/),[h·ng] / [ml],2972.5,146637,DB00950,Fexofenadine
,33256506,area under the plasma concentration-time curve from zero to infinity (AUCinf),"The peak maximum plasma concentration (C max) and the area under the plasma concentration-time curve from zero to infinity (AUCinf) mean value of FEX with BRE and placebo-treated groups were 699 ng/mL vs. 710 ng/mL and 2972.5 ng⋅h/mL vs. 3460.5 ng⋅h/mL, respectively.","Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33256506/),[h·ng] / [ml],3460.5,146638,DB00950,Fexofenadine
,17301733,half-maximal inhibitions,"Naringin and hesperidin's half-maximal inhibitions were 3.6 and 2.7 microM, respectively.",Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17301733/),μM,3.6,155361,DB00950,Fexofenadine
,17301733,half-maximal inhibitions,"Naringin and hesperidin's half-maximal inhibitions were 3.6 and 2.7 microM, respectively.",Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17301733/),μM,2.7,155362,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,28.0,156443,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,5.1,156444,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,9.9,156445,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,2.8,156446,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22. 9,156447,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,14.7,156448,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22.3,156449,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,11.1,156450,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,39.6,156451,DB00950,Fexofenadine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,26,156452,DB00950,Fexofenadine
,20045385,flow rate,The flow rate was 0.2 ml/min and the total run time was 2 min.,Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20045385/),[ml] / [min],0.2,156701,DB00950,Fexofenadine
,20045385,total run time,The flow rate was 0.2 ml/min and the total run time was 2 min.,Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20045385/),min,2,156702,DB00950,Fexofenadine
,26819931,Tmax,LST-18 succeeded in increasing oral FXD bioavailability by 62% and reducing Tmax to 2.16 h.,Enhancement of the Oral Bioavailability of Fexofenadine Hydrochloride via Cremophor(®) El-Based Liquisolid Tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26819931/),h,2.16,157603,DB00950,Fexofenadine
,32959922,Tmax,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,1.5,158149,DB00950,Fexofenadine
,32959922,Tmax,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,1,158150,DB00950,Fexofenadine
,32959922,terminal elimination half-life,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,10.6,158151,DB00950,Fexofenadine
,32959922,terminal elimination half-life,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,10.8,158152,DB00950,Fexofenadine
,32078103,fraction absorbed,The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.,"Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078103/),,1.0,161619,DB00950,Fexofenadine
,20863200,AUC(0-∞),"However, AUC(0-∞) of oral fexofenadine was a significantly higher in LPS-treated animals (13.9 ± 9.76 min · µg/ml) compared to controls (5.53 ± 1.12 min · µg/ml).",Pharmacokinetics of fexofenadine following LPS administration to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863200/),[min·μg] / [ml],13.9,174859,DB00950,Fexofenadine
,20863200,AUC(0-∞),"However, AUC(0-∞) of oral fexofenadine was a significantly higher in LPS-treated animals (13.9 ± 9.76 min · µg/ml) compared to controls (5.53 ± 1.12 min · µg/ml).",Pharmacokinetics of fexofenadine following LPS administration to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863200/),[min·μg] / [ml],5.53,174860,DB00950,Fexofenadine
,22124880,IC₅₀,"The uptake of [¹⁴C]aliskiren and [³H]fexofenadine was linear in OATP1A2-expressing cells and was reduced by naringin, with IC₅₀ values of 75.5 ± 11.6 and 24.2 ± 2.0 μM, respectively.",Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22124880/),μM,75.5,175449,DB00950,Fexofenadine
,22124880,IC₅₀,"The uptake of [¹⁴C]aliskiren and [³H]fexofenadine was linear in OATP1A2-expressing cells and was reduced by naringin, with IC₅₀ values of 75.5 ± 11.6 and 24.2 ± 2.0 μM, respectively.",Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22124880/),μM,24.2,175450,DB00950,Fexofenadine
,19552748,AUC(0-infinity),"During the control phase, the mean AUC(0-infinity) of S(-)- and R(+)-fexofenadine was 700 ng h(-1) ml(-1)[95% confidence interval (CI) 577, 823] and 1202 ng h(-1) ml(-1) (95% CI 1007, 1396), respectively, with a significant difference (P < 0.001).",Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),[ng] / [h·ml],700,182565,DB00950,Fexofenadine
,19552748,AUC(0-infinity),"During the control phase, the mean AUC(0-infinity) of S(-)- and R(+)-fexofenadine was 700 ng h(-1) ml(-1)[95% confidence interval (CI) 577, 823] and 1202 ng h(-1) ml(-1) (95% CI 1007, 1396), respectively, with a significant difference (P < 0.001).",Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),[ng] / [h·ml],1202,182566,DB00950,Fexofenadine
,19552748,R/S ratio,The R/S ratio for the AUC(0-infinity) was reduced from 1.76 to 1.32 (P < 0.001) by verapamil treatments.,Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),,1.76,182567,DB00950,Fexofenadine
,19552748,R/S ratio,The R/S ratio for the AUC(0-infinity) was reduced from 1.76 to 1.32 (P < 0.001) by verapamil treatments.,Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),,1.32,182568,DB00950,Fexofenadine
,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,38,187392,DB00950,Fexofenadine
,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,201,187393,DB00950,Fexofenadine
>,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,467,187394,DB00950,Fexofenadine
>,32715985,dissolution number (Dn),"The dose number (D0) values were <1 whereas, all the dissolution number (Dn) values were >1 at the same dose level.",Applying Biopharmaceutical Classification System criteria to predict the potential effect of Cremophor® RH 40 on fexofenadine bioavailability at higher doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32715985/),,1,188308,DB00950,Fexofenadine
,26213156,R/S ratio,"Subsequently, GFJ increased the mean R/S ratio of the AUC0-24 from 1.58 to 1.96 (P < 0.05).",The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26213156/),,1.58,189645,DB00950,Fexofenadine
,26213156,R/S ratio,"Subsequently, GFJ increased the mean R/S ratio of the AUC0-24 from 1.58 to 1.96 (P < 0.05).",The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26213156/),,1.96,189646,DB00950,Fexofenadine
,32311673,AUC0-∞,"Enantiomeric ratio in plasma (AUC0-∞(R)-(+)/(S)-(-)) was close to 1.5, nevertheless in urine was closed to unity.",Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311673/),,1.5,192497,DB00950,Fexofenadine
,32311673,transplacental transfer,The transplacental transfer was approximately 18% for both fexofenadine enantiomers.,Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311673/),%,18,192498,DB00950,Fexofenadine
,16084853,area under the curve from time 0 to infinity (AUC(0-infinity)),"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194.0 +/- 1910.8 and 4040.4 +/- 1832.2 ng.mL(-1).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [ml],5194.0,194084,DB00950,Fexofenadine
,16084853,area under the curve from time 0 to infinity (AUC(0-infinity)),"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194.0 +/- 1910.8 and 4040.4 +/- 1832.2 ng.mL(-1).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [ml],4040.4,194085,DB00950,Fexofenadine
,16084853,oral clearance (CL/F),"h(-1), respectively (P = .271), and the oral clearance (CL/F) was 530.9 +/- 191.1 and 806.0 +/- 355.3 mL.h(-1).kg(-1), respectively (P = .096).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],530.9,194086,DB00950,Fexofenadine
,16084853,oral clearance (CL/F),"h(-1), respectively (P = .271), and the oral clearance (CL/F) was 530.9 +/- 191.1 and 806.0 +/- 355.3 mL.h(-1).kg(-1), respectively (P = .096).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],806.0,194087,DB00950,Fexofenadine
,16084853,AUC(0-infinity),"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [h·ml],"15,630.6",194088,DB00950,Fexofenadine
,16084853,AUC(0-infinity),"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [h·ml],9252.9,194089,DB00950,Fexofenadine
,16084853,CL/F,"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],167.0,194090,DB00950,Fexofenadine
,16084853,CL/F,"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],292.3,194091,DB00950,Fexofenadine
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.13,200647,DB00950,Fexofenadine
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.16,200648,DB00950,Fexofenadine
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.12,200649,DB00950,Fexofenadine
,26577375,flow rate,The elution was isocratic at ambient temperature with a flow rate of 1.0 mL/min.,HPLC Determination of Fexofenadine in Human Plasma For Therapeutic Drug Monitoring and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26577375/),[ml] / [min],1.0,203092,DB00950,Fexofenadine
,26577375,total time,The total time for a chromatographic separation was ~6.5 min.,HPLC Determination of Fexofenadine in Human Plasma For Therapeutic Drug Monitoring and Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26577375/),min,6.5,203093,DB00950,Fexofenadine
,31317804,kobs,These findings were supported by the result that the kobs (0.00000118 min-1) of bergamottin for CYP3A was lower than the kdeg (0.0005 min-1) for CYP3A.,Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317804/),1/[min],0.00000118,205759,DB00950,Fexofenadine
,31317804,kdeg,These findings were supported by the result that the kobs (0.00000118 min-1) of bergamottin for CYP3A was lower than the kdeg (0.0005 min-1) for CYP3A.,Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317804/),1/[min],0.0005,205760,DB00950,Fexofenadine
,14586383,effective jejunal permeability,"The mean (+/-SD) effective jejunal permeability values were 0.06 +/- 0.07. 10(-4) cm/s and 0.04 +/- 0.07. 10(-4) cm/s in the control and treatment periods, respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[cm] / [s],0.06,215145,DB00950,Fexofenadine
,14586383,effective jejunal permeability,"The mean (+/-SD) effective jejunal permeability values were 0.06 +/- 0.07. 10(-4) cm/s and 0.04 +/- 0.07. 10(-4) cm/s in the control and treatment periods, respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[cm] / [s],0.04,215146,DB00950,Fexofenadine
,14586383,apparent absorption rate constant into the systemic circulation,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),1/[min],0.0030,215147,DB00950,Fexofenadine
,14586383,area under the plasma concentration-time curve,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[ng] / [min·ml],161,215148,DB00950,Fexofenadine
,14586383,area under the plasma concentration-time curve,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[ng] / [min·ml],664,215149,DB00950,Fexofenadine
,21189907,maximum plasma concentration of fexofenadine (T(max)),"In all subjects time taken for maximum plasma concentration of fexofenadine (T(max)) was around 3 h and the value of average maximum plasma concentration was 460.63 ng/mL, the effect of fexofenadine on the heart (measured as QTc interval prolongation) was maximum (E(max)) after 6 h and average QTc interval was 469.75 ms.",QTc interval prolongation by fexofenadine in healthy human volunteers and its correlation with plasma levels of fexofenadine: A demonstration of anticlockwise hysteresis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189907/),h,3,215741,DB00950,Fexofenadine
,21189907,maximum plasma concentration,"In all subjects time taken for maximum plasma concentration of fexofenadine (T(max)) was around 3 h and the value of average maximum plasma concentration was 460.63 ng/mL, the effect of fexofenadine on the heart (measured as QTc interval prolongation) was maximum (E(max)) after 6 h and average QTc interval was 469.75 ms.",QTc interval prolongation by fexofenadine in healthy human volunteers and its correlation with plasma levels of fexofenadine: A demonstration of anticlockwise hysteresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189907/),[ng] / [ml],460.63,215742,DB00950,Fexofenadine
,21189907,E(max),"In all subjects time taken for maximum plasma concentration of fexofenadine (T(max)) was around 3 h and the value of average maximum plasma concentration was 460.63 ng/mL, the effect of fexofenadine on the heart (measured as QTc interval prolongation) was maximum (E(max)) after 6 h and average QTc interval was 469.75 ms.",QTc interval prolongation by fexofenadine in healthy human volunteers and its correlation with plasma levels of fexofenadine: A demonstration of anticlockwise hysteresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189907/),h,6,215743,DB00950,Fexofenadine
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,6.5,216135,DB00950,Fexofenadine
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,7.9,216136,DB00950,Fexofenadine
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],382.8,216447,DB00950,Fexofenadine
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],63.0,216448,DB00950,Fexofenadine
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],84.5,216449,DB00950,Fexofenadine
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],47.4,216450,DB00950,Fexofenadine
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"2,950",216451,DB00950,Fexofenadine
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"2,327",216452,DB00950,Fexofenadine
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"2,095",216453,DB00950,Fexofenadine
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"1,008",216454,DB00950,Fexofenadine
,27023466,AUC0-2h,"While geometric mean folic acid AUC0-2h, which mainly reflects absorption, was 0.403 and 0.414 mg/L·h before and after the vitamin D3 course (geometric mean ratio (GMR), 1.027; 90 % confidence interval (90 % CI), 0.788-1.340), the geometric mean fexofenadine AUC0-2h was 1.932 and 2.761 mg/L·h, respectively (GMR, 1.429; 90 % CI, 0.890-2.294).","No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27023466/),[mg] / [h·l],0.403,217163,DB00950,Fexofenadine
,27023466,AUC0-2h,"While geometric mean folic acid AUC0-2h, which mainly reflects absorption, was 0.403 and 0.414 mg/L·h before and after the vitamin D3 course (geometric mean ratio (GMR), 1.027; 90 % confidence interval (90 % CI), 0.788-1.340), the geometric mean fexofenadine AUC0-2h was 1.932 and 2.761 mg/L·h, respectively (GMR, 1.429; 90 % CI, 0.890-2.294).","No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27023466/),[mg] / [h·l],0.414,217164,DB00950,Fexofenadine
,27023466,AUC0-2h,"While geometric mean folic acid AUC0-2h, which mainly reflects absorption, was 0.403 and 0.414 mg/L·h before and after the vitamin D3 course (geometric mean ratio (GMR), 1.027; 90 % confidence interval (90 % CI), 0.788-1.340), the geometric mean fexofenadine AUC0-2h was 1.932 and 2.761 mg/L·h, respectively (GMR, 1.429; 90 % CI, 0.890-2.294).","No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27023466/),[mg] / [h·l],1.932,217165,DB00950,Fexofenadine
,27023466,AUC0-2h,"While geometric mean folic acid AUC0-2h, which mainly reflects absorption, was 0.403 and 0.414 mg/L·h before and after the vitamin D3 course (geometric mean ratio (GMR), 1.027; 90 % confidence interval (90 % CI), 0.788-1.340), the geometric mean fexofenadine AUC0-2h was 1.932 and 2.761 mg/L·h, respectively (GMR, 1.429; 90 % CI, 0.890-2.294).","No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27023466/),[mg] / [h·l],2.761,217166,DB00950,Fexofenadine
,24038489,apparent oral clearance,"In patients with glomerulonephritis, the apparent oral clearance of fexofenadine (representing transporter activity) was 58.8 ± 34.4 L/hour, documenting a 40% reduction compared with previous data in healthy controls.",In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24038489/),[l] / [h],58.8,231001,DB00950,Fexofenadine
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],699,239417,DB00950,Fexofenadine
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],1346,239418,DB00950,Fexofenadine
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4133,239419,DB00950,Fexofenadine
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],11287,239420,DB00950,Fexofenadine
,16669847,Cmax,"In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],704,239421,DB00950,Fexofenadine
,16669847,"AUC0, infinity","In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4433,239422,DB00950,Fexofenadine
,20306185,area under the time versus concentration curve,The area under the time versus concentration curve of fexofenadine in the metronidazole phase (2075.7 ng h/mL) was similar to that of the placebo phase (1999.2 ng h/mL) (P = 0.356).,"Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306185/),[h·ng] / [ml],2075.7,240608,DB00950,Fexofenadine
,20306185,area under the time versus concentration curve,The area under the time versus concentration curve of fexofenadine in the metronidazole phase (2075.7 ng h/mL) was similar to that of the placebo phase (1999.2 ng h/mL) (P = 0.356).,"Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306185/),[h·ng] / [ml],1999.2,240609,DB00950,Fexofenadine
,20306185,maximum plasma levels,"Additionally, metronidazole did not affect the maximum plasma levels of fexofenadine (304.4 ng/mL for placebo vs. 293.2 ng/mL for metronidazole) (P = 0.423).","Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306185/),[ng] / [ml],304.4,240610,DB00950,Fexofenadine
,20306185,maximum plasma levels,"Additionally, metronidazole did not affect the maximum plasma levels of fexofenadine (304.4 ng/mL for placebo vs. 293.2 ng/mL for metronidazole) (P = 0.423).","Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306185/),[ng] / [ml],293.2,240611,DB00950,Fexofenadine
,9818712,steady-state ratio,A 63:37 steady-state ratio of R(+) and S(-) fexofenadine was observed in plasma.,Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818712/),,63,240979,DB00950,Fexofenadine
,18702885,maximum plasma concentration,"Mean maximum plasma concentration of fexofenadine was 224 ng/mL, and mean area under the plasma concentration curve was 898 ng . hour/mL.","Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18702885/),[ng] / [ml],224,247355,DB00950,Fexofenadine
,18702885,area under the plasma concentration curve,"Mean maximum plasma concentration of fexofenadine was 224 ng/mL, and mean area under the plasma concentration curve was 898 ng . hour/mL.","Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18702885/),[h·ng] / [ml],898,247356,DB00950,Fexofenadine
,16502766,plasma AUC,"The plasma AUC for fexofenadine (mean +/- SEM) was higher (2.7-to 2.3-fold, p < 0.001) after application to the jejunum (1090 +/- 134 h x ng/ml) than to the ileum (404 +/- 102 h x ng/ml) or colon (476 +/- 212 h x ng/ml).","Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),[h·ng] / [ml],1090,247426,DB00950,Fexofenadine
,16502766,plasma AUC,"The plasma AUC for fexofenadine (mean +/- SEM) was higher (2.7-to 2.3-fold, p < 0.001) after application to the jejunum (1090 +/- 134 h x ng/ml) than to the ileum (404 +/- 102 h x ng/ml) or colon (476 +/- 212 h x ng/ml).","Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),[h·ng] / [ml],404,247427,DB00950,Fexofenadine
,16502766,plasma AUC,"The plasma AUC for fexofenadine (mean +/- SEM) was higher (2.7-to 2.3-fold, p < 0.001) after application to the jejunum (1090 +/- 134 h x ng/ml) than to the ileum (404 +/- 102 h x ng/ml) or colon (476 +/- 212 h x ng/ml).","Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),[h·ng] / [ml],476,247428,DB00950,Fexofenadine
,16502766,tmax,The administration of erythromycin affected the absorption rate after jejunal application with a prolonged tmax from a median of 40 min (range 10-90 min) to a median of 3 hours (range 10-180 min) (p = 0.009).,"Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),min,40,247429,DB00950,Fexofenadine
,16502766,tmax,The administration of erythromycin affected the absorption rate after jejunal application with a prolonged tmax from a median of 40 min (range 10-90 min) to a median of 3 hours (range 10-180 min) (p = 0.009).,"Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),h,3,247430,DB00950,Fexofenadine
,16502766,plasma AUC,The concomitant administration of erythromycin in the jejunum tended to increase the plasma AUC of fexofenadine from 1090 +/- 134 to 1750 +/- 305 h x ng/ml (p = 0.069).,"Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),[h·ng] / [ml],1090,247431,DB00950,Fexofenadine
,16502766,plasma AUC,The concomitant administration of erythromycin in the jejunum tended to increase the plasma AUC of fexofenadine from 1090 +/- 134 to 1750 +/- 305 h x ng/ml (p = 0.069).,"Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502766/),[h·ng] / [ml],1750,247432,DB00950,Fexofenadine
,11823753,50% inhibitory concentration [IC(50)],"6',7'-Dihydroxybergamottin had modest inhibitory activity (50% inhibitory concentration [IC(50)], 33 micromol/L).",Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823753/),[μM] / [l],33,257354,DB00950,Fexofenadine
,11823753,IC(50),"6',7'-Dihydroxybergamottin potently inhibited rat oatp3 and oatp1 (IC(50), 0.28 micromol/L).",Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823753/),[μM] / [l],0.28,257355,DB00950,Fexofenadine
,21280267,area under the plasma concentration-time curve (AUC),"T] allele showed a significant decrease in fexofenadine in the area under the plasma concentration-time curve (AUC) compared with c.[1457C] + c[= ] subjects (1110 ± 347 vs. 1762 ± 542 ng . h/ml, P< 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],1110,258865,DB00950,Fexofenadine
,21280267,area under the plasma concentration-time curve (AUC),"T] allele showed a significant decrease in fexofenadine in the area under the plasma concentration-time curve (AUC) compared with c.[1457C] + c[= ] subjects (1110 ± 347 vs. 1762 ± 542 ng . h/ml, P< 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],1762,258866,DB00950,Fexofenadine
,21280267,AUC,"When administered with apple juice, a significant decrease in the fexofenadine AUC was observed compared with water (1342 ± 519 vs. 284 ± 79.2 ng . h/ml, P < 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],1342,258867,DB00950,Fexofenadine
,21280267,AUC,"When administered with apple juice, a significant decrease in the fexofenadine AUC was observed compared with water (1342 ± 519 vs. 284 ± 79.2 ng . h/ml, P < 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],284,258868,DB00950,Fexofenadine
,28756848,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8±4.0% and 64.4%, fexofenadine: 6.5±0.7% and 7.9%, respectively, in bioavailability).",Using Improved Serial Blood Sampling Method of Mice to Study Pharmacokinetics and Drug-Drug Interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756848/),%,6.5,261614,DB00950,Fexofenadine
,28756848,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8±4.0% and 64.4%, fexofenadine: 6.5±0.7% and 7.9%, respectively, in bioavailability).",Using Improved Serial Blood Sampling Method of Mice to Study Pharmacokinetics and Drug-Drug Interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756848/),%,7.9,261615,DB00950,Fexofenadine
